-
Innovation Ranking
NewInnovation Ranking – Korea Zinc Co Ltd
Korea Zinc Co Ltd (Korea Zinc) is a non-ferrous metal smelting company that carries out the development and acquisition of base metals, precious metals, rare metals, and other metal properties. The company’s product portfolio includes base metals, precious metals, rare metals, and others. It offers a range of metals which comprise zinc, lead, copper, gold, silver, bismuth, indium, antimony, cadmium, cobalt, and tellurium, among others. Korea Zinc’s products find application in photoengraving plates; storage battery pastes; radiation shielders; cable sheathing;...
-
Innovation Ranking
NewInnovation Ranking – Yunnan Chihong Zinc and Germanium Co Ltd
Yunnan Chihong Zinc and Germanium Co Ltd (Chihong) is a mining and mineral exploration company. The company explores and develops lead, copper, silver, zinc, gold, non-ferrous metals and mineral resource deposit properties. It serves in the areas such as manufacturing and production services; strategic exploration, scientific research and development; product industrialization, information consulting, international trade with other strategic emerging industries, mineral resources exploration, energy conservation and emission reduction; resource utilization efficiency and product deep processing. The company operates in Canada,...
-
Sector Analysis
NewZinc Mining Market Analysis by Reserves, Production, Assets, Demand Drivers and Forecast to 2030
Zinc Mining Market Report Overview The zinc production increased for the third year in a row to 12.26 million tonnes (mt) in 2023 with China, Peru, Australia, India, and the US being the key contributors. Global zinc production was impacted by operational disruptions as well as low zinc prices in 2023. However, the zinc production output is expected to grow by 2.0% in 2024, but will relatively remain relatively flat in 2025, with a CAGR of less than 1% during...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Abequolixron Zinc in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Abequolixron Zinc in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Abequolixron Zinc in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
Zinc Finger Protein GLI1 – Drugs In Development, 2023
Global Markets Direct’s Zinc Finger Protein GLI1 provides in depth analysis on Zinc Finger Protein GLI1 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Zinc Finger Protein...
-
Product Insights
CXXC Type Zinc Finger Protein 5 – Drugs In Development, 2023
Global Markets Direct’s CXXC Type Zinc Finger Protein 5 provides in depth analysis on CXXC Type Zinc Finger Protein 5 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved...
-
Product Insights
Plomosas Zinc Project
The Plomosas Zinc Project is a zinc mine in Mexico. It is currently in operation. Empower your strategies with our Plomosas Zinc Project report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abequolixron Zinc in Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Abequolixron Zinc in Lymphoma Drug Details: RGX-104 is under development for the treatment of epithelial...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abequolixron Zinc in Endometrial Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Abequolixron Zinc in Endometrial Cancer Drug Details: RGX-104 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abequolixron Zinc in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Abequolixron Zinc in Solid Tumor Drug Details: RGX-104 is under development for the treatment of...